Table 1.
Association between TrkA expression and clinicopathological parameters in human breast carcinomas.
| TrkA Intensity | |||||
|---|---|---|---|---|---|
| Parameter | 0 | 1 | 2 | 3 | p-Value |
| All Cases (n = 366) | 260 (71%) | 27 (7%) | 48 (13%) | 31 (9%) | |
| Pathological Subtype | <0.0001 a | ||||
| DCIS (n = 50) | 38 (76%) | 12 (24%) | 0 (0%) | 0 (0%) | |
| ILC (n = 158) | 126 (80%) | 7 (4%) | 19 (12%) | 6 (4%) | |
| IDC (n = 158) | 96 (61%) | 8 (5%) | 29 (18%) | 25 (16%) | |
| Clinical Parameters in Invasive Carcinomas | |||||
| Patient Age (Years) | 0.7195 | ||||
| ≤50 (n = 184) | 130 (71%) | 7 (4%) | 30 (16%) | 17 (9%) | |
| >50 (n = 132) | 92 (70%) | 8 (6%) | 18 (14%) | 14 (10%) | |
| Lymph Node Status (N) | 0.0696 | ||||
| Negative (n = 163) | 121 (74%) | 9 (6%) | 21 (13%) | 12 (7%) | |
| Positive (n = 133) | 82 (62%) | 6 (5%) | 27 (20%) | 18 (13%) | |
| HER2 | 0.0027 a | ||||
| HER2 negative (n = 250) | 188 (75%) | 10 (4%) | 31 (12%) | 21 (9%) | |
| HER2 positive (n = 66) | 34 (51%) | 5 (8%) | 17 (26%) | 10 (15%) | |
| Estrogen Receptor | 0.2267 | ||||
| ER negative (n = 181) | 129 (71%) | 5 (3%) | 27 (15%) | 20 (11%) | |
| ER positive (n = 135) | 93 (69%) | 10 (7%) | 21 (16%) | 11 (8%) | |
| Progesterone Receptor | 0.0261 a | ||||
| PR negative (n = 207) | 152 (73%) | 6 (3%) | 26 (13%) | 23 (11%) | |
| PR positive (n = 109) | 70 (64%) | 9 (8%) | 22 (20%) | 8 (8%) | |
| Tumour Size (T) | 0.6360 | ||||
| 1 + 2 (n = 238) | 166 (70%) | 14 (6%) | 36 (15%) | 22 (9%) | |
| 3 + 4 (n = 58) | 38 (65%) | 1 (2%) | 11 (19%) | 8 (14%) | |
TrkA = tyrosine kinase receptor A; DCIS = ductal carcinoma in situ; ILC = invasive lobular carcinomas; IDC = invasive ductal carcinomas; HER2 = human EGF receptor 2; ER = estrogen receptor; PR = progesterone receptor; TNBC = triple-negative breast cancer (ER-/PR-/HER2-). a Statistically significant p-values (p < 0.05 using chi-square test).